novo nordisk oral semaglutide Approved to Reduce the Risk of Cardiovascular Events Article » PBD

Given these clinical trial design challenges, we explore specific issues and potential solutions in planning a large-scale GLP-1 receptor agonist and cancer prevention trial

doi: 10.1007/s00401-010-0655-4 163 UrbanMEnotDPDallmannGKornerLForcherVEnohPet al

DRESS and AGEP reactions to iodinated contrast media: a French case series

Alteration of several metabolic enzymes and pathways that affect KG abundance and KGDD activity have been reported in cancer, such as mutations of IDH1 and IDH2, changes in glutaminolysis that deplete KG, or alterations in fumarate hydratase (FH) and succinate dehydrogenase (SDH) that inhibit KGDD activity (Losman et al., 2020)

Sometimes, it may even be fatal